Inhibition of the methionine aminopeptidase 2 enzyme for the treatment of obesity

Diabetes, Metabolic Syndrome and Obesity

Volumn 7, Issue , 2014, Pages 73-84

  Joharapurkar, Amit A ^a   Dhanesha, Nirav A ^a   Jain, Mukul R ^a  

^a ZYDUS RESEARCH CENTRE   (India)

Author keywords

Angiogenesis; Anti obesity; Beloranib; Body weight; Metap2

Indexed keywords

AMFEBUTAMONE PLUS NALTREXONE; AMFEBUTAMONE PLUS ZONISAMIDE; BELORANIB; CDK 732; CETILISTAT; CKD 732; FUMAGILLIN; FUMAGILLOL CHLOROACETYLCARBAMATE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GSK 598809; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROLASE INHIBITOR; LORCASERIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MELANOCORTIN RECEPTOR AGONIST; METHIONYL AMINOPEPTIDASE 2; METHIONYL AMINOPEPTIDASE 2 INHIBITOR; PANCREAS POLYPEPTIDE; PHENTERMINE; PHENTERMINE PLUS TOPIRAMATE; PLACEBO; PP 1420; PRAMLINTIDE; RM 493; TESOFENSINE; TETRAHYDROLIPSTATIN; TT 401; UNCLASSIFIED DRUG; VELNEPERIT; ZGN 201; ZGN 433; ZGN 440; ZP 2929;

ABNORMAL FECES COMPOSITION; ABSENCE OF SIDE EFFECTS; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANXIETY; CARDIOVASCULAR DISEASE; DECREASED APPETITE; DEPRESSION; DIARRHEA; DIET RESTRICTION; DIZZINESS; DRUG DOSE COMPARISON; DRUG STRUCTURE; DRUG TARGETING; ENERGY EXPENDITURE; ENZYME INHIBITION; EXERCISE; FATIGUE; FATTY STOOL; HEADACHE; HUMAN; INJECTION SITE CONTUSION; INJECTION SITE PAIN; INJECTION SITE REACTION; INSOMNIA; LIFESTYLE MODIFICATION; MEDICAL DECISION MAKING; MENTAL DISEASE; NAUSEA; NAUSEA AND VOMITING; NONHUMAN; OBESITY; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SOMNOLENCE; WEIGHT REDUCTION;

EID: 84896045360     PISSN: None     EISSN: 11787007     Source Type: Journal    
DOI: 10.2147/DMSO.S56924     Document Type: Review

References (94)

1. World Health Organization [webpage on the Internet]. Media centre fact sheets. Obesity and overweight. Geneva: World Health Organization; 2013. Available from: http://www.who.int/mediacentre/factsheets/fs311/en/index.html. Accessed October 22, 2013.
2. Kumanyika SK, Obarzanek E, Stettler N, et al; American Heart Association Council on Epidemiology and Prevention, Interdisciplinary Committee for Prevention. Population-based prevention of obesity: the need for comprehensive promotion of healthful eating, physical activity, and energy balance: a scientific statement from American Heart Association Council on Epidemiology and Prevention, Interdisciplinary Committee for Prevention (formerly the expert panel on population and prevention science). Circulation. 2008;118(4):428-464.
3. Ogden CL, Yanovski SZ, Carroll MD, Flegal KM. The epidemiology of obesity. Gastroenterology. 2007;132(6):2087-2102.
4. Nguyen DM, El-Serag HB. The epidemiology of obesity. Gastroenterol Clin North Am. 2010;39(1):1-7.
5. Dietz WH, Gortmaker SL. Do we fatten our children at the television set? Obesity and television viewing in children and adolescents. Pediatrics.1985;75(5):807-812.
6. Holsten JE. Obesity and the community food environment: a systematic review. Public Health Nutr. 2009;12(3):397-405.
7. Prentice AM, Jebb SA. Obesity in Britain: gluttony or sloth? BMJ. 1995;311(7002):437-439.
8. Andreasen CH, Andersen G. Gene-environment interactions and obesity further aspects of genomewide association studies. Nutrition. 2009;25(10):998-1003.
9. Andreasen CH, Stender-Petersen KL, Mogensen MS, et al. Low physical activity accentuates the effect of the FTO rs9939609 polymorphism on body fat accumulation. Diabetes. 2008;57(1):95-101.
10. Christakis NA, Fowler JH. The spread of obesity in a large social network over 32 years. N Engl J Med. 2007;357(4):370-379.
11. Heal DJ, Gosden J, Smith SL. Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders. Br J Clin Pharmacol. 2009;68(6):861-874.
12. Adams KF, Schatzkin A, Harris TB, et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med. 2006;355(8):763-778.
13. Oster G, Thompson D, Edelsberg J, Bird AP, Colditz GA. Lifetime health and economic benefits of weight loss among obese persons. Am J Public Health. 1999;89(10):1536-1542.
14. Wu T, Gao X, Chen M, van Dam RM. Long-term effectiveness of dietplus-exercise interventions vs diet-only interventions for weight loss: a meta-analysis. Obes Rev. 2009;10(3):313-323.
15. Adan RA. Mechanisms underlying current and future anti-obesity drugs. Trends Neurosci. 2013;36(2):133-140.
16. Adan RA. Mechanisms underlying current and future anti-obesity drugs. Trends Neurosci. 2013;36(2):133-140.
17. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1(1):27-31.
18. Cao Y. Angiogenesis modulates adipogenesis and obesity. J Clin Invest. 2007;117(9):2362-2368.
19. Bukowiecki L, Lupien J, Follea N, Paradis A, Richard D, LeBlanc J. Mechanism of enhanced lipolysis in adipose tissue of exercise-trained rats. Am J Physiol. 1980;239(6):E422-E429.
20. Gupta RK, Mepani RJ, Kleiner S, et al. Zfp423 expression identifies committed preadipocytes and localizes to adipose endothelial and perivascular cells. Cell Metab. 2012;15(2):230-239.
21. Cao Y. Endogenous angiogenesis inhibitors and their therapeutic implications. Int J Biochem Cell Biol. 2001;33(4):357-369.
22. Sun K, Wernstedt Asterholm I, Kusminski CM, et al. Dichotomous effects of VEGF-A on adipose tissue dysfunction. Proc Natl Acad Sci U S A. 2012;109(15):5874-5879.
23. Dobson DE, Kambe A, Block E, et al. 1-Butyryl-glycerol: a novel angiogenesis factor secreted by differentiating adipocytes. Cell. 1990;61(2):223-230.
24. Mahadev K, Wu X, Donnelly S, Ouedraogo R, Eckhart AD, Goldstein BJ. Adiponectin inhibits vascular endothelial growth factor-induced migration of human coronary artery endothelial cells. Cardiovasc Res. 2008;78(2):376-384.
25. Lijnen HR. Angiogenesis and obesity. Cardiovasc Res. 2008;78(2): 286-293.
26. Kawaguchi N, Toriyama K, Nicodemou-Lena E, Inou K, Torii S, Kitagawa Y. De novo adipogenesis in mice at the site of injection of basement membrane and basic fibroblast growth factor. Proc Natl Acad Sci U S A. 1998;95(3):1062-1066.
27. Davis S, Aldrich TH, Jones PF, et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell. 1996;87(7):1161-1169.
28. Christiaens V, Lijnen HR. Angiogenesis and development of adipose tissue. Mol Cell Endocrinol. 2010;318(1-2):2-9.
29. Davis S, Papadopoulos N, Aldrich TH, et al. Angiopoietins have distinct modular domains essential for receptor binding, dimerization and superclustering. Nat Struct Biol. 2003;10(1):38-44.
30. Hadi HA, Suwaidi JA. Endothelial dysfunction in diabetes mellitus. Vasc Health Risk Manag. 2007;3(6):853-876.
31. Zafrir B. Brown adipose tissue: research milestones of a potential player in human energy balance and obesity. Horm Metab Res. 2013;45(11):774-785.
32. Yoneshiro T, Aita S, Matsushita M, et al. Recruited brown adipose tissue as an antiobesity agent in humans. J Clin Invest. 2013;123(8):3404-3408.
33. Virtanen KA, Lidell ME, Orava J, et al. Functional brown adipose tissue in healthy adults. N Engl J Med. 2009;360(15):1518-1525.
34. Saito M, Okamatsu-Ogura Y, Matsushita M, et al. High incidence of metabolically active brown adipose tissue in healthy adult humans: effects of cold exposure and adiposity. Diabetes. 2009;58(7):1526-1531.
35. Kuo LE, Kitlinska JB, Tilan JU, et al. Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med. 2007;13(7):803-811.
36. Tam J, Duda DG, Perentes JY, Quadri RS, Fukumura D, Jain RK. Blockade of VEGFR2 and not VEGFR1 can limit diet-induced fat tissue expansion: role of local versus bone marrow-derived endothelial cells. PLoS One. 2009;4(3):e4974.
37. Cao R, Brakenhielm E, Wahlestedt C, Thyberg J, Cao Y. Leptin induces vascular permeability and synergistically stimulates angiogenesis with FGF-2 and VEGF. Proc Natl Acad Sci U S A. 2001;98(11):6390-6395.
38. Escudier B, Eisen T, Stadler WM, et al; TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125-134.
39. Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358(19): 2039-2049.
40. Steinbrook R. The price of sight ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med. 2006;355(14): 1409-1412.
41. Rupnick MA, Panigrahy D, Zhang CY, et al. Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci U S A. 2002;99(16):10730-10735.
42. Duh E, Aiello LP. Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox. Diabetes. 1999;48(10): 1899-1906.
43. Gariano RF, Gardner TW. Retinal angiogenesis in development and disease. Nature. 2005;438(7070):960-966.
44. Jackson R, Hunter T. Role of methionine in the initiation of haemoglobin synthesis. Nature. 1970;227(5259):672-676.
45. Solbiati J, Chapman-Smith A, Miller JL, Miller CG, Cronan JE. Processing of the N termini of nascent polypeptide chains requires deformylation prior to methionine removal. J Mol Biol. 1999;290(3): 607-614.
46. Selvakumar P, Pasha MK, Ashakumary L, Dimmock JR, Sharma RK. Myristoyl-CoA:protein N-myristoyltransferase: a novel molecular approach for cancer therapy (Review). Int J Mol Med. 2002;10(4): 493-500.
47. Bradshaw RA, Brickey WW, Walker KW. N-terminal processing: the methionine aminopeptidase and N alpha-acetyl transferase families. Trends Biochem Sci. 1998;23(7):263-267.
48. Arfin SM, Kendall RL, Hall L, et al. Eukaryotic methionyl aminopeptidases: two classes of cobalt-dependent enzymes. Proc Natl Acad Sci U S A. 1995;92(17):7714-7718.
49. Selvakumar P, Lakshmikuttyamma A, Das U, Pati HN, Dimmock JR, Sharma RK. NC2213: a novel methionine aminopeptidase 2 inhibitor in human colon cancer HT29 cells. Mol Cancer. 2009;8:65.
50. Catalano A, Romano M, Robuffo I, Strizzi L, Procopio A. Methionine aminopeptidase-2 regulates human mesothelioma cell survival: role of Bcl-2 expression and telomerase activity. Am J Pathol. 2001;159(2):721-731.
51. Ingber D, Fujita T, Kishimoto S, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature. 1990;348(6301):555-557.
52. Yeh JR, Ju R, Brdlik CM, et al. Targeted gene disruption of methionine aminopeptidase 2 results in an embryonic gastrulation defect and endothelial cell growth arrest. Proc Natl Acad Sci U S A. 2006;103(27): 10379-10384.
53. White HM, Acton AJ, Considine RV. The angiogenic inhibitor TNP-470 decreases caloric intake and weight gain in high-fat fed mice. Obesity (Silver Spring). 2012;20(10):2003-2009.
54. Brakenhielm E, Cao Y. Angiogenesis in adipose tissue. Methods Mol Biol. 2008;456:65-81.
55. Kim YM, An JJ, Jin YJ, et al. Assessment of the anti-obesity effects of the TNP-470 analog, CKD-732. J Mol Endocrinol. 2007;38(4):455-465.
56. Hughes TE, Kim DD, Marjason J, Proietto J, Whitehead JP, Vath JE. Ascending dose-controlled trial of beloranib, a novel obesity treatment for safety, tolerability, and weight loss in obese women. Obesity (Silver Spring). 2013;21(9):1782-1788.
57. Datta B, Majumdar A, Datta R, Balusu R. Treatment of cells with the angiogenic inhibitor fumagillin results in increased stability of eukaryotic initiation factor 2-associated glycoprotein, p67, and reduced phosphorylation of extracellular signal-regulated kinases. Biochemistry. 2004;43(46):14821-14831.
58. Raghow R, Yellaturu C, Deng X, Park EA, Elam MB. SREBPs: the crossroads of physiological and pathological lipid homeostasis. Trends Endocrinol Metab. 2008;19(2):65-73.
59. Kotzka J, Knebel B, Avci H, et al. Phosphorylation of sterol regulatory element-binding protein (SREBP)-1a links growth hormone action to lipid metabolism in hepatocytes. Atherosclerosis. 2010;213(1): 156-165.
60. Hughes TE, Kim DD, Marjason J, Proietto J, Whitehead JP, Vath JE. Ascending dose-controlled trial of beloranib, a novel obesity treatment for safety, tolerability, and weight loss in obese women. Obesity (Silver Spring). 2013;21(9):1782-1788.
61. Baratta R, Amato S, Degano C, et al. Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies. J Clin Endocrinol Metab. 2004;89(6):2665-2671.
62. Zhang P, Nicholson DE, Bujnicki JM, et al. Angiogenesis inhibitors specific for methionine aminopeptidase 2 as drugs for malaria and leishmaniasis. J Biomed Sci. 2002;9(1):34-40.
63. Zafgen [webpage on the Internet]. Cambridge: Zafgen; 2013. Available from: http://zafgen.com/zafgen/our-approach/the-science. AccessedOctober 22, 2013.
64. Lijnen HR, Frederix L, Van Hoef B. Fumagillin reduces adipose tissue formation in murine models of nutritionally induced obesity. Obesity(Silver Spring). 2010;18(12):2241-2246.
65. Sin N, Meng L, Wang MQ, Wen JJ, Bornmann WG, Crews CM. The anti-angiogenic agent fumagillin covalently binds and inhibits themethionine aminopeptidase, MetAP-2. Proc Natl Acad Sci U S A. 1997;94(12):6099-6103.
66. Killough JH, Magill GB. A comparative study of fumagillin and oxytetracycline in amebiasis. Am J Trop Med Hyg. 1954;3(6): 999-1007.
67. Kusaka M, Sudo K, Fujita T, et al. Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent. Biochem Biophys Res Commun. 1991;174(3):1070-1076.
68. Garrabrant T, Tuman RW, Ludovici D, et al. Small molecule inhibitors of methionine aminopeptidase type 2 (MetAP-2). Angiogenesis. 2004;7(2):91-96.
69. Bråkenhielm E, Cao R, Gao B, et al. Angiogenesis inhibitor, TNP470, prevents diet-induced and genetic obesity in mice. Circ Res. 2004;94(12):1579-1588.
70. Rupnick MA, Panigrahy D, Zhang CY, et al. Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci U S A. 2002;99(16):10730-10735.
71. White HM, Acton AJ, Considine RV. The angiogenic inhibitor TNP-470 decreases caloric intake and weight gain in high-fat fed mice. Obesity (Silver Spring). 2012;20(10):2003-2009.
72. Chun E, Han CK, Yoon JH, Sim TB, Kim YK, Lee KY. Novel inhibitors targeted to methionine aminopeptidase 2 (MetAP2) strongly inhibit the growth of cancers in xenografted nude model. Int J Cancer. 2005;114(1):124-130.
73. Kim YM, An JJ, Jin YJ, et al. Assessment of the anti-obesity effects of the TNP-470 analog, CKD-732. J Mol Endocrinol. 2007;38(4): 455-465.
74. Hughes TE, Nichols AJ, Vath JE. ZGN-201 (ZGN), a methionine aminopeptidase 2 (MetAP2) inhibitor, durably eliminates excess body fat in obese mice through regulation of fat metabolism and food intake. Poster presented at: European Association for the Study of Diabetes; September 20-24, 2010; Stockholm, Sweden. Presentation 244.
75. Hughes TE, Vath JE, Scott MF, et al. ZGN -201, a methionine aminopeptidase 2 inhibitor, normalizes glucose tolerance in overweight dogs. Abstract presented at: American Diabetes Association's 70th Scientific Sessions; June 25-29, 2010. Orlando, FL. Abstract number 24-LB.
76. Zafgen [website on the Internet]. Press releases. Cambridge: Zafgen; 2013. Available from: http://zafgen.com/zafgen/newsroom/pressreleases. Accessed October 22, 2013.
77. Cao Y. Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases. Nat Rev Drug Discov. 2010;9(2):107-115.
78. Powell AG, Apovian CM, Aronne LJ. New drug targets for the t{stroke}reatment of obesity. Clin Pharmacol Ther. 2011;90(1):40-51.
79. US Food and Drug Administration. Orlistat. City: Publisher; Year. Available from: http://www.fda.gov/downloads/drugs/development approvalprocess/developmentresources/ucm163348.pdf. Accessed October 22, 2013.
80. Drugs Information Online [website on the Internet]. Phentermine. City: Drugs.com; 2014. Available from: http://www.drugs.com/monograph/phentermine.html. Accessed on October 22, 2013.
81. US Food and Drug Administration [website on the Internet]. FDA approves Belviq to treat some overweight or obese adults. Silver Spring: US Food and Drug Administration: 2012. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm309993.htm. Accessed on October 22, 2013.
82. US Food and Drug Administration [website on the Internet]. FDA approves weight-management drug Qysmia. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312468.htm. Accessed October 22, 2013.
83. Gadde KM, Yonish GM, Foust MS, Wagner HR. Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study. J Clin Psychiatry. 2007;68(8):1226-1229.
84. Appel L, Bergström M, Buus Lassen J, Långström B. Tesofensine, a novel triple monoamine re-uptake inhibitor with anti-obesity effects: Dopamine transporter occupancy as measured by PET. Eur Neuropsychopharmacol. 2013.
85. Kopelman P, Groot Gde H, Rissanen A, et al. Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical). Obesity (Silver Spring). 2010;18(1):108-115.
86. Naltrexone/bupropion: Contrave(R); naltrexone SR/bupropion SR. Drugs R D. 2010;10(1):25-32.
87. Hughes TE, Kim DD, Marjason J, Proietto J, Whitehead JP, Vath JE. Ascending dose-controlled trial of beloranib, a novel obesity treatment for safety, tolerability, and weight loss in obese women. Obesity (Silver Spring). 2013;21(9):1782-1788.
88. Drugs Information Online [website on the Internet]. Shionogi announces positive top-line efficacy results from year-long studies of Velneperit, a novel NPY Y5 receptor antagonist being investigated for the treatment of obesity. City: Drugs.com; 2014. Available from: http://www.drugs.com/clinical_trials/shionogi-announces-positive-top-line-efficacyresults-year-long-studies-velneperit-novel-npy-y5-6742.html. Accessed October 22, 2013.
89. Rhythm Pharmaceuticals, Inc. Phase 2 study to evaluate safety and efficacy of rm-493 in obese patients. Available from: http://clinicaltrials.gov/show/NCT01749137. NLM Identifier: NCT01749137. Accessed October 22, 2013.
90. Bristol-Myers Squibb. A study to examine the long term effect of Pramlintide on body weight in obese subjects. Available from: http://clinicaltrials.gov/ct2/show/NCT00189514?term=Pramlintide&rank=4. NLM Identifier: NCT00189514. Accessed October 22, 2013.
91. Transitiontherapeutics.com TT-401. Available from http://www.transitiontherapeutics.com/media/news.php. Accessed on October 22, 2013.
92. Tan TM, Field BC, Minnion JS, et al. Pharmacokinetics, adverse effects and tolerability of a novel analogue of human pancreatic polypeptide, PP 1420. Br J Clin Pharmacol. 2012;73(2):232-239.
93. Dodds CM, O'Neill B, Beaver J, et al. Effect of the dopamine D3 receptor antagonist GSK598809 on brain responses to rewarding food images inoverweight and obese binge eaters. Appetite. 2012;59(1):27-33.
94. ZEAL& [webpage on the Internet]. ZP-2929. Glostrup: Zealand Pharma A/s; 2012. Available from: http://www.zealandpharma.com/productpipeline/cardio-metabolic-diseases/drug-candidates-for-diabetes-andmetabolic-diseases/zp2929. Accessed October 22, 2013.